Supernus Pharmaceuticals (NASDAQ:SUPN) PT Raised to $43.00

Supernus Pharmaceuticals (NASDAQ:SUPN) had its price objective lifted by Piper Sandler from $42.00 to $43.00 in a research report issued on Thursday, Benzinga reports. The firm currently has an “overweight” rating on the specialty pharmaceutical company’s stock. Piper Sandler’s target price indicates a potential upside of 61.35% from the company’s previous close.

Separately, StockNews.com cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 27th.

Supernus Pharmaceuticals Stock Performance

NASDAQ SUPN opened at $26.65 on Thursday. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of 65.00 and a beta of 1.08. The stock’s 50 day moving average price is $26.86 and its two-hundred day moving average price is $30.69. Supernus Pharmaceuticals has a 52 week low of $21.99 and a 52 week high of $42.09.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of $0.13 by ($0.42). The firm had revenue of $153.88 million during the quarter, compared to the consensus estimate of $143.39 million. Supernus Pharmaceuticals had a net margin of 4.20% and a return on equity of 2.83%. The company’s revenue was down 13.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.03 EPS. On average, equities research analysts forecast that Supernus Pharmaceuticals will post 1.34 EPS for the current year.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, VP Tami Tillotson Martin sold 5,135 shares of the firm’s stock in a transaction on Friday, August 25th. The stock was sold at an average price of $31.59, for a total transaction of $162,214.65. Following the completion of the sale, the vice president now owns 85,249 shares of the company’s stock, valued at approximately $2,693,015.91. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 8.76% of the company’s stock.

Institutional Trading of Supernus Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. Glass Jacobson Investment Advisors llc acquired a new stake in shares of Supernus Pharmaceuticals during the 2nd quarter worth about $30,000. China Universal Asset Management Co. Ltd. raised its stake in Supernus Pharmaceuticals by 96.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,401 shares of the specialty pharmaceutical company’s stock worth $39,000 after purchasing an additional 687 shares in the last quarter. Public Employees Retirement System of Ohio raised its stake in Supernus Pharmaceuticals by 41.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 1,253 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 368 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Supernus Pharmaceuticals by 389.7% in the 1st quarter. Tower Research Capital LLC TRC now owns 1,327 shares of the specialty pharmaceutical company’s stock worth $48,000 after purchasing an additional 1,056 shares in the last quarter. Finally, Point72 Middle East FZE acquired a new stake in Supernus Pharmaceuticals in the 4th quarter worth about $57,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.